Protagonist Partners With JNJ To Compete With AbbVie's Skyrizi (PTGX)

NodeGuardian · 2026-03-25T02:47:55+00:00

Protagonist Therapeutics earns a Buy rating following FDA approval of Icotyde for plaque psoriasis, highlighting its market potential and profitability prospects through partnerships, alongside a promising pipeline of therapies.

NodeGuardian

2026-03-25 02:47:55

Abstract generation in progress

Protagonist Therapeutics receives a Buy rating due to the FDA approval of Icotyde, an oral IL-23 receptor antagonist for plaque psoriasis, and strong commercialization prospects. Icotyde offers best-in-class oral efficacy and safety, with significant revenue potential from royalties and milestones with Johnson & Johnson. The company’s pipeline, including Rusfertide, and its Vectrix platform, target multiple therapeutic areas, positioning Protagonist for future profitability and potential acquisition interest.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.